Gujarat Themis Biosyn Completes MicroBiopharm Japan Acquisition

Transaction Value: JPY 21.5 billion
GTBL Investment: ₹475 crore equity contribution and ₹745 crore loan to subsidiary

Reader Takeaway: Global CDMO expansion strengthens growth prospects, but successful integration and funding execution remain key.

What just happened

Gujarat Themis Biosyn Limited (GTBL) has completed the acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (MBJ). The acquisition was executed through Themis Biosyn Japan Limited, GTBL's wholly owned subsidiary in Japan.

The company had first announced the transaction on May 22, 2026. The deal has now closed after completion of customary closing conditions and regulatory approvals.

The total consideration for the acquisition is JPY 21.5 billion. The transaction has been funded through a combination of debt and equity.

GTBL has contributed ₹475 crore as capital into its Japanese subsidiary and extended a loan of ₹745 crore. The company has also entered into a loan agreement with Themis Biosyn Japan Limited for up to ₹800 crore.

Why this matters

The acquisition significantly expands GTBL's capabilities in fermentation-based pharmaceutical manufacturing and contract development and manufacturing services (CDMO).

Through MBJ, the company gains access to a proprietary P450 enzyme platform for precision fermentation, helping expand beyond conventional chemical manufacturing processes.

The transaction also broadens GTBL's product portfolio by adding capabilities in APIs and intermediates for oncology, immunosuppressants, peptides and antibiotics.

The backstory

MBJ brings more than six decades of fermentation expertise along with biotechnology capabilities including plasmid DNA, antibody-drug conjugation (ADC) technologies and recombinant proteins.

The acquisition also adds three GMP-compliant manufacturing facilities with inspection track records from the US FDA and Japan's PMDA. Around 40% of MBJ's revenue is generated from markets outside Japan, providing GTBL with broader international exposure.

What changes now

GTBL will integrate MBJ into its global operations through its Japanese subsidiary.

Management believes the acquisition supports its strategy of becoming a globally integrated fermentation-focused CDMO while strengthening relationships with international pharmaceutical companies.

Risks to watch

Investors should monitor the integration of MBJ into GTBL's operations, execution of the funding structure, utilization of the loan facilities and the financial contribution of the acquired business over the coming quarters.